Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol). (PATROL)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00891124
First received: April 28, 2009
Last updated: November 2, 2009
Last verified: November 2009

April 28, 2009
November 2, 2009
May 2009
Not Provided
Proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline [ Time Frame: At baseline and Endpiont (after 2months) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00891124 on ClinicalTrials.gov Archive Site
The treatment goal of risk factors is based on ADA guideline. [ Time Frame: At baseline and Endpiont (after 2months) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
A Multi-center, Prospective, Observational Study to Assess the Effect of Patient Education Related to CV Risk Factors in Type 2 Diabetes Mellitus

This study will address the proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline, among outpatients coming to the Korean primary care nationwide.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Type II DM and Hypertension and/or Hyperlipidemia

  • Glycemia
  • Hypertension
  • Hyperlipidemia
Not Provided
1
Type II DM and Hypertension and/or Hyperlipidemia
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4045
October 2009
Not Provided

Inclusion Criteria:

  • Patients who had been diagnosed with type II diabetes mellitus
  • Patients with hypertension and / or hyperlipidemia
  • Patients who had agreed to Informed

Exclusion Criteria:

  • Patients who had been diagnosed with type I diabetes mellitus
  • Patients with neither hypertension and hyperlipidemia
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT00891124
NIS-CKR-DUM-2009/2
No
AstraZeneca
AstraZeneca
Not Provided
Study Director: Joonwoo Bahn ASTRAZENECA, Korea Medical Department
AstraZeneca
November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP